Diagnostic technique for disturbed thrombocyte aggregation accompanying mucoviscidosis in children
SUBSTANCE: invention represents a diagnostic technique for the disturbed thrombocyte aggregation accompanying mucoviscidosis in children involving a thrombocyte aggregation test using the Multiplate aggregometer inducers. Trays with a magnetic mixer and electrodes are added with NaCl 400 mcl at 37°C and immediately added with whole blood 400 mcl from a hirudin test tube, incubated in the chamber for two minutes; the tray is added with 30 mcl of an aggregation inducer specified in a group: soluble thrombin receptor - peptid-6, adenosine diphosphate, arachidonic acid. The thrombocyte aggregation rate is displayed on the screen in the form of a curve, and the sub-curve area U is automatically calculated; the sub-curve area U shows the thrombocyte aggregation state as compared to reference values in the group of healthy children; if the threshold area U has appeared to exceed the reference, the thrombocyte hyperaggregation, while the threshold area U being less than the reference, the thrombocyte hypoaggregation is stated.
EFFECT: invention provides the timely diagnosis of microcirculatory disorders accompanying mucoviscidosis.
2 ex, 1 dwg
The invention relates to medicine, namely to Hematology for the diagnosis of conditions with increased thrombogenic risk and can be used to detect hidden violations of platelet hemostasis at the microcirculatory level in children with cystic fibrosis.
According to genetic studies, the prevalence of cystic fibrosis (MB) in Russia is more than 1 in 10,000 newborns. Given the characteristics and the clinical course of cystic fibrosis in children and are more likely to develop various complications, the urgent task is the study of platelet hemostasis. Special attention should be paid to the ratio of inflammatory changes in inflammation (in loko morbi) and systemic inflammation in chronic obstructive pathology, as the inflammatory response with increased activity of Pro-inflammatory factors in bronchopulmonary system can move up to the level of systemic blood flow. Data pathological changes are characterized by subclinical chronic inflammatory reaction with low activity, which is manifested by disturbances in the microvasculature.
There is a method of study of intravascular platelet aggregation in vitro. The essence of the method lies in the fact that produce blood, stabilize it, the separation of the plasma is at and erythrocytes with obtaining platelet-rich plasma, disaggregation of platelets, the analysis of the obtained data, which is judged on the degree of aggregation, stabilization of blood after collection carried out by the sodium citrate 3.8% in the ratio of 9:1, the separation of blood with obtaining platelet-rich plasma is conducted by centrifugation, prior to the introduction of desegregate part of the platelet-rich plasma get depleted, for samples of each patient determine the extreme values of transmittance, depleted platelet-plasma - 100% light transmission, platelet-rich plasma - 0%, after the introduction of disaggregation off curve disaggregation, which captures the value of the maximum radius value of disaggregation, which is judged on the degree of intravascular platelet aggregation (Patent RF №2102754).
There is a method of assessing the influence of platelet aggregation factors of hemostasis when performing clinical and functional studies, including the study of blood plasma, with platelet-rich plasma is divided into two aliquots, the first and second and only in the first aliquot perform irreversible platelet aggregation under the influence of the inductor, the modified first aliquot and the initial second synchronous centrifuged receive the first and second case, platelet-poor plasma, separately determined in the first and second aliquot contained in poor what rombaldoni plasma identical factors calculate the difference between them and the consumption and release of these factors assess the degree of platelet aggregation factors of hemostasis (RF Patent No. 2179318).
There is a method of study of platelet aggregation, namely, that of platelet-rich plasma is placed in a chamber rheoscope, mix and measure the integral optical density of all units, the integral optical density of all of the aggregates formed by the interaction of cells, the integral optical density of each unit at the end of the aggregation process and calculate the index R agregatirovanija by the formula: R=K/N×100%, where K is the number of large units with integral optical density of more than 151 srvc. units; M is the total number of units with integral optical density greater than 10 services. units; 100% is the factor that determines the percentage relationship of K/N (RF Patent No. 2421724).
The known method of detecting violations of platelet aggregation, for which take blood, secrete platelet-rich plasma and put on a glass slide, where they test for platelet aggregation with multiple inductors. Visual assessment of platelet aggregation under these conditions allows a small volume of 0.02 ml) of plasma and a small amount of inductors to simulate real-world conditions krovat the ka when using the minimum vzaimootmenyaemy concentrations of inducers with the mandatory inclusion in the combination of collagen and calculates an average value of the induction of aggregation by collagen, largest of which is judged on thin violations of the aggregation capacity of platelets. (Patent RF №2393485). The way we have chosen as a prototype.
The disadvantage of this method is the use of blood plasma, obtained by centrifugation, separation of plasma, the calculation of the coefficients of induction of aggregation.
The objective of the invention is to develop a method for the diagnosis of disorders of platelet aggregation to identify violations platelet hemostasis in cystic fibrosis children.
The technical result of the implementation of the method is that the diagnosis of disorders of platelet aggregation allows you to notice any change in the microvasculature in cystic fibrosis and conduct therapeutic correction of these violations.
The method consists in the fact that conduct tests on platelet aggregation with inductors in whole blood in children with cystic fibrosis, as well as the aggregation inductors are used: soluble thrombin receptor-peptide-6 (TRAP-6), the solution by acid (ADP) or arachidonic acid.
The method is as follows.
Platelet aggregation is determined in whole blood on aggregometry "Multiplate" (VD, Germany). Blood should be used within 30 minutes after intake. No reservation is centrifuged the e and secretion of platelet-rich plasma. In a cuvette with a magnetic stirrer and electrode add 400 ál NaCl(3 mmol/l) at 37°C and then add 400 ál of whole blood from a test tube with hirudin. Incubated in the chamber of the device for two minutes, then add in the cuvette 30 μl of aggregation inducer selected from the group: peptide -6 (TRAP-6), adenosine diphosphate (ADP) or arachidonic acid. In each cuvette add one inductor and incubated for 6 minutes. The rate of platelet aggregation assessed on the screen of the device along the curve aggregation and area under the curve (U), which is calculated by aggregometry automatically (Fig.1). Measurement of platelet aggregation spend impedance method. Impedance (eng. impedance, from lat. impedio - inhibit) - method study of the electrical double layer, mechanism and kinetics of the processes at the electrode - electrolyte interface, which is based on the measurement of impedance - the impedance of the electrochemical cell and the dependence of this resistance on the frequency of the alternating current. The cell includes researched and auxiliary electrodes between which the electrolyte.
The device draws a curve aggregation on the graph on the Y axis is the rate of formation of aggregates, and on the X-axis the time. The value of the area under the curve U is judged on the state of aggregation of platelets. For each activator: peptide -6(TRAP-6), arachidonic acid, adenosine diphosphate (ADP) under the tsya separate graphics.
Then, assess the area under the curve U in comparison with the reference intervals for different age groups defined in healthy children:
0.1 to 12 months.: (TRAP-6) 32-78 U; ADP 24-83 U; arachidonic acid 27-73 U;
1,1-4 years: (TRAP-6) 43-90 U; ADP 32-75 U; arachidonic acid 45-90 U;
5-9 years: (TRAP-6) 58-95 U; ADP 35-74 U; arachidonic acid 56-90 U;
10-18 years: (TRAP-6) 54-97 U; ADP 28-74 U; arachidonic acid 52-88 U.
The U value higher than the maximum reference value corresponding age group demonstrates hyperaggregation platelets with this inducer of aggregation.
The U value is below the threshold, the corresponding age group demonstrates hypogravity platelets with the inductor.
On the basis of the obtained data it can be concluded that the changes occurring in the body of a sick child with cystic fibrosis can affect the aggregation capacity of platelets. In case of detection of violations of aggregation correction of dysfunction platelet hemostasis purpose, in addition to the basic therapy, drugs with angioprotective action: origin, endotelon, angiojet, arginine and antiplatelet properties: pentoxifylline, cardiomagnyl, plaice.
These laboratory tests can be used in the diagnosis of platelet disorders C is s hemostasis in cystic fibrosis children. We studied 50 patients with cystic fibrosis with pulmonary gastrointestinal form ages 3 months and up to 15 years. The control group consisted of 40 healthy children of the same age. The diagnosis of cystic fibrosis was staged on the basis of positive sweat test (>60 mmol/l concentrations of sodium and chloride in sweat fluid) and confirmed by genetic studies.
The invention meets the criterion of "novelty", because currently there is no way to detect changes in the aggregation properties of platelets with cystic fibrosis, and therefore, prevention of disturbances of microcirculation, ischemic changes in the focus of inflammation.
We have shown that routine methods, namely the definition of the standard indicators of the General analysis of blood, coagulation, often does not give us a full picture of the processes occurring at the microcirculatory level.
Clinical example 1.
Girl, J. E., 3 years was in the Department of pulmonology and Allergology with a diagnosis of Testoviron of the pancreas (mucoviscidosis E 84.0), genotype 218ins A/ 2143 delT, pulmonary, intestinal form, severe. Chronic diffuse bronchitis. NAM 1 degree. Complaint: on wet cough productive cough with a moderate number (on average, 50 ml) yellow-gray sputum, poor weight gain. Sick 2 months, when there was a dry joke is obrazny cough with viscous sputum and lumps of thick green mucus. In the survey by place of residence suspected diagnosis of cystic fibrosis, which was confirmed by laboratory tests (chloride sweat 147 mmol/l). A further survey was carried out in the ncla Russian Academy of medical Sciences Department of pulmonology and Allergology. The diagnosis is confirmed by genetic studies. When viewed noteworthy low physical development of the child. Weight 11,8 kg; increase of 92.5 see At laboratory examination the following indicators of a blood: erythrocytes 4,82x1012/l, hemoglobin 127 g/l, leucocytes 6,12xl0%; erythrocyte sedimentation rate of 7 mm/h, platelets 448x109/liter coagulogram violations have been found. Conducted tests to assess the aggregation of platelets. Revealed the following values: peptide TRAP-6 - 27 U (reference values 43-90 U); ADP - 17 U (reference values 32-75 U); arachidonic acid 12 U (reference values 45-90 U), which shows that hypogravity platelets. These changes characterize a violation of platelet aggregation in the microcirculation level under normal number of platelets in the peripheral blood. On the basis of the received data to the basic therapy was added menadione, calcium and magnesium. After 14 days of repeated study of platelet aggregation. The obtained data aggregation: with TRAP-6 - 84 U; ADP - 27 U; arachidonic acid - 61 U (significance level was p<0,05). On the fo is e therapy was noted positive dynamics of the broncho-pulmonary system, perhaps due to the correction of disorders of platelet aggregation in the microcirculation level.
Clinical example 2.
Girl A., 7 years was in the Department of pulmonology and Allergology diagnosed with:
cystic fibrosis, mixed, severe. Chronic diffuse bronchitis.Common cylindrical bronchiectasis in both lungs. Malnutrition 1-11 degree. The formation of pulmonary heart. Pulmonary hypertension. Secondary angiopathy of the retina. Complaints on frequent paroxysmal cough, difficulty breathing, shortness of breath, recurrent headaches. With the birth of the noted bad weight gain, frequent pneumonia. Diagnosed in 3 months, confirmed genetically - heterozygote for del F508. Periodically arise hemoptysis. When viewed chest inflated, breathing weakened on both sides, bilateral diffuse dry rales. HR 118 in minutes NPV 22 minutes In the analysis of blood revealed:
erythrocytes 4,95xl012/l, hemoglobin 130 g/l leucocytes 20,7xl09/l, platelets 564x10% ESR 6 mm /h. Platelet aggregation: with TRAP-6 - 125 U (reference values 58-95 U),c ADP-78 U (reference values 35-74 U), and arachidonic acid - 101 U (reference values 56-90 U), which shows that hyperaggregation platelets. On the basis of these indicators to the basic therapy of added metabolic therapy, appointed: carnitine,vitamin E, B and trental with antiagregatini and angioprotective action. After 14 days the aggregation of platelets in the dynamics was: with TRAP-6 - 95 U, and ADP - 59 U.
Thus, noted the positive dynamics in the aggregation properties of platelets, which resulted in the normalization of indicators. The circulation in the blood vessels of various organs associated with the formation of microthrombi in the blood flow and subsidence of these clots in small blood vessels. The child had angiopathy of the retina, which can also serve as a manifestation of metabolic disorders in platelets and rheology at the level of the microvasculature. As a result of insufficient supply of oxygen affected the function of target organs (lungs, bronchi, digestive system) with the formation of microthrombi in the blood flow and subsidence of these clots in small blood vessels.
The study of the aggregation of platelets facilitates timely diagnosis violation of the aggregation properties of platelets and their correction by assigning the necessary preparations in addition to the basic therapy that eliminates the endothelial dysfunction and platelet aggregation at the level of microcirculation and helps patients in conditions of tissue hypoxia.
The advantages of the proposed method for the diagnosis of disorders of platelet link hemo the pelvis in children is the use of whole blood, inductors add in standard doses, use the impedance method of measurement, the results of which are presented as area under the curve (U), and not in seconds, which gives the additional ability of platelet aggregation.
Method for the diagnosis of disorders of platelet aggregation in cystic fibrosis children, including test platelet aggregation with inductors, wherein the platelet aggregation is determined in whole blood on aggregometry "Multiplate", while in the cuvette with a magnetic stirrer and electrode add 400 ál of NaCl at 37°C and then add 400 ál of whole blood from a test tube with hirudin, incubated in the chamber of the device for two minutes, then add in the cuvette 30 μl of the inductor aggregation, selected from the group of soluble thrombin receptor - peptide-6, adenosine diphosphate, arachidonic acid, while the rate of platelet aggregation is displayed on the screen of the device in the form of a curve and automatically calculated the area under the curve U, the value of the area under the curve U is judged on the state of aggregation of trombocytes in comparison with the reference values in the group of healthy children and with increasing thresholds square U above reference judge hyperaggregation platelets, and at lower thresholds square U below the reference judge hypogravity platelets.
SUBSTANCE: invention refers to medicine, particularly to clinical biochemistry, and aims at determining oxidative protein modification in a substance pool of an average molecular weight in a biological medium accompanying any pathological conditions by biochemical examination. The biological medium specified in the blood plasma, erythrocyte or urine is sampled; proteins are deposited by adding 10% trichloroacetic acid; if observing sedimentation, a centrifugation cycle follows at 1000 rpm for 15 minutes; thereafter, 2,4-dinitrophenylhydrazine 0.05 M in hydrochloric acid 2 M is added; the sample is centrifuged at 1000 rpm for 20 minutes; and if observing sedimentation, the sediment is washed twice in ethanol-ethylacetate (1:1), dried on a water bath for 10 minutes and dissolved in urea 8 M; the sample is kept in a boiling water bath for 10 minutes until dissolved completely; the prepared solution is analysed by spectrophotometry. The method is applicable both for single use, and for monitoring of the postoperative oxidation protein modification and average molecule levels.
EFFECT: method provides higher information value of biochemical tests, reducing consumption of the biological material.
9 tbl, 2 ex
SUBSTANCE: invention includes determination of content of soluble fibrin and D-dimers, formed in the process of fibrinolysis, activated in blood sample. In method, in accordance with the claimed invention, level of D-dimers, corresponding to destruction of soluble fibrin and level of D-dimers in sample with border values of the norm, are compared.
EFFECT: test in accordance with the claimed invention can be applied for determining whether resistance to blood coagulation in patient is sufficient.
4 tbl, 3 ex, 2 dwg
SUBSTANCE: method for thrombin activity test in an initially non-reacted mixture of thrombin and fibrinogen (versions) involving the stages: (a) reversible thrombin inhibition by adding an inhibitory solution having pH varying within the range of 8.5 to 11.5; (b) addition of the known amount of fibrinogen to the mixture (or the known amount of a chromogenic or fluorogenic thrombin substrate), (c) reversible thrombin activation by pH reduction to approximately 6.0 to less than 8.5, (d) enabling thrombin reacting with fibrinogen, (e) thrombin activity test initially found in the dry mixture. The method for fibrinogen functionality test in an initially non-reacted mixture of thrombin and fibrinogen (versions) involving the stages: (a) reversible thrombin inhibition by adding an inhibitory solution having pH varying within the range of 8.5 to 11.5; (b) addition of the known amount of thrombin to the mixture (or a thrombin-like enzyme), (c) reversible thrombin activation by pH reduction to approximately 6.0 to less than 8.5, (d) enabling thrombin reacting with fibrinogen, (e) fibrinogen functionality test initially found in the dry mixture.
EFFECT: group of inventions enables higher accuracy of thrombin and fibrinogen activity test.
32 cl, 1 dwg
SUBSTANCE: analyser has a revolving cuvette with a sample in which there is a control ferromagnetic ball, a magnet which can interact with said ball, a coagulation sensor which transmits signals from the ball and having a Hall sensor and a magnet, a signal processing device in form of a power supply unit, a Hall sensor, a microprocessor and a display device included in a common measuring circuit. The analyser is multi-channelled by fitting at least one additional revolving cuvette to form several channels. All cuvettes lie in a temperature-controlled unit included in the common measuring circuit. The longitudinal axis of each cuvette is inclined at an acute angle to the vertical. In the coagulation sensor, the magnet lies opposite the Hall sensor on the opposite side of the cuvette. The magnet is in form of a flat cylinder mounted with possibility of displacement along the cuvette. The analyser is also fitted with a unit for controlling rotation of the cuvettes and, included in the common measuring a circuit, a measurement parameter adjustment unit having rewritable read-only memory, and a timer configured to automatically switch on when a reactant is fed into the cuvette.
EFFECT: use of the invention increases reliability and broadens functional capabilities of the analyser owing to use of a multichannel measuring circuit, and simplifies the measuring procedure by automating the process.
4 cl, 2 dwg
SUBSTANCE: blood plasma is examined in 4 minutes after the beginning of spontaneous red blood cell aggregation for free red blood cell count and cell count in aggregates. A percentage of non-aggregated red blood cells (PNA RBC) by formula PNA RBC=FRBSC×100/(TRBCA+FRBSC) wherein FRBSC is the free red blood cell count, TRBCA are total red blood cells in aggregates. If the PNA RBC is 56 to 30%, I degree of severity is stated, 30% to 4% - II degree of severity, less than 4% - III degree of severity.
EFFECT: use of the invention enables objectifying and increasing precision of evaluation of red blood cell aggregation, evaluating an intensity of patient's microcirculation disorders in a relatively short time, and thereby ensuring well-timed adequate complex of therapeutic measures or corrected therapy.
SUBSTANCE: quantity of fibrin-monomers, dissolved in 0.5 N sodium hydroxide, is determined spectrophotometrically with application of ethanol test. Claimed method of quantitative determination of fibrin-monomers in blood makes it possible to reveal pathological process in organism with 95% reliability.
EFFECT: increase of determination accuracy.
2 tbl, 4 ex
SUBSTANCE: thrombosis monitor comprises: a thrombosis chamber, at least in a part of which there is a thrombogenic material; an inlet tube connected to the thrombosis chamber through which blood flows into the thrombosis chamber; a blood supply container connected to the inlet tube; a feed pump for the container; a pressure sensor for measuring pressure applied to the container. A method of thrombosis monitoring consists in the fact that after introduction of an anticoagulant, blood is supplied from the container to the thrombosis chamber by pressing on a fluid placed on a blood layer and having density less than that of the blood layer; it is combined with anticoagulation blood processing or blood coagulation stimulation, and measurement of pressure applied to the container; the thrombogenic material is placed at least in a part of the thrombosis chamber.
EFFECT: group of inventions provides overall assessment of blood coagulation and platelet-cell thrombosis in a medium equivalent to blood flow for evaluation of efficacy of an antithrombotic drug.
11 cl, 15 dwg, 23 ex
SUBSTANCE: for determination of functional state of hemostasis system record of blood coagulation process is performed, current amplitude of blood resistance in first time moment is registered and second resistance of blood at multiple time moment from initial time value is measured. Two resistances and time moments are used to determine maximum blood resistance and time constant, by which blood resistance at the beginning and end of coagulation process is calculated. Obtained parameters are used to determine indices of beginning and end of blood coagulation process. Obtained indices are compared with of the same name indices of blood coagulation process in norm and in case of differently directed deviations disturbances of functional state of hemostasis system are diagnosed.
EFFECT: invention makes it possible to increase measurement accuracy and reduce examination time.
1 tbl, 4 dwg
SUBSTANCE: method is based on a method of observing turbidimetric fibrin clot formation with optical transmission of an incubation medium recorded by ultraviolet radiation band 230 to 320 nm by means of UV-spectrophotometre as a fibrin-polymer detector.
EFFECT: invention enables higher accuracy and sensitivity of the method.
4 ex, 4 dwg
SUBSTANCE: for thrombin production measurement, a layer of said sample contacts with a fluorogenic substratum of thrombin where the thickness of said layer is 0.05 to 5 mm, while the surface area is 10 to 500 mm2. Further, the thrombin production environment in said sample is provided. It is followed by measuring the fluorescence emitted from the layer surface by a fluorescent group released by the fluorescent substratum as a result of an enzymatic action of produced thrombin on said fluorogenic substratum. Besides, the invention ensures a kit for measuring the thrombin activity in the sample.
EFFECT: higher measuring accuracy.
29 cl, 12 dwg, 5 ex
SUBSTANCE: invention relates to the field of microbiology, namely to a method of microorganism characteristic. The essence of the method consists in the following: (a) obtaining a sample to be tested, about which it is known that it contains or can contain microorganisms; (b) layering the tested sample on a density buffer in a container, where the said density buffer possesses a uniform density from approximately 1.025 to approximately 1.120 g/ml; (c) addition of an identifier into the said tested sample and/or into the said density buffer; (d) centrifugation of the said container in order to separate microorganisms from other components of the said tested sample and to form a deposit of microorganisms; (e) spectroscopic analysis of the deposit and/or the said one or more than one identifier with obtaining measurements, which characterise the microorganisms, where the said spectroscopic analysis is carried out when the said deposit is located in the said container; and (f) characteristic of the microorganisms in the deposit on the basis of the obtained measurements and/or the presence or absence of the said identifier or a metabolised form of the said identifier in the deposit, where the said microorganisms are characterised by one or more classification models, selected from the group, consisting of Gram groups, clinical Gram groups, therapeutic and functional groups.
EFFECT: application of the claimed invention makes it possible to increase the accuracy of the microorganism characteristic.
15 cl, 5 dwg, 1 tbl, 4 ex
SUBSTANCE: invention refers to medicine, namely to qualitative differential instant diagnostic technique for benign and malignant periglottis new growths as shown by oral fluid biomarkers. Substance of the method consists in measuring a quantity of matrix metalloproteinase 2 (MMP 2) in patient's oral fluid; the clinical reference is the level of 1.7-2.9 ng/ml; if the MMP 2 content is 14.4-24.3 ng/ml, patient's periglottis papilloma is diagnosed; if the patient's oral fluid MMP 2 content is 4.1-6.8 ng/ml, periglottis cancer is diagnosed. A biomarker for the qualitative differential instant diagnosis of the periglottis new growths is a tissue inhibitor of metalloproteinase 2 (TIMP 2); the clinical reference is a level of 6.44-11.23 ng/ml; if the TIMP 2 content 29.25-48.75 ng/ml, patient's periglottis papilloma is diagnosed; the TIMP 2 content being 57.23-95.03 ng/ml, periglottis cancer is diagnosed.
EFFECT: using the declared technique enables providing more accurate differential diagnosis of the benign and malignant periglottis new growths.
2 cl, 6 ex
SUBSTANCE: method is implemented by preparing an incubation solution No.1 containing sulphanilic acid 500 mg in 1 M HCl 50 ml, and solution No.2 consisting of NaNO2 125 ml in distilled water 2.5 ml. Each solution is taken in an amount of 1 ml, mixed in a test tube and added with whole blood with a coagulate 200 mcl. The reaction is carried out for 10 min at a room temperature, and a drop of the suspension is used to produce a multilayer smear on a slide, dried and studied by computed cytophotometry.
EFFECT: more accurate determination.
SUBSTANCE: invention refers to medicine, namely diagnostics and can be used for assessing threatened foetal death following the aggravated cytomegalovirus infection at the early stages of gestation. To this effect, with the underlying cytomegalovirus infection, peripheral blood of a pregnant woman is analysed to measure the anti-cytomegalovirus IgG antibody titre and progesterone level. If the anti-cytomegalovirus IgG titre is 1:1600, and the progesterone level is 18.5±0.8 nmole/l, a threatened spontaneous miscarriage is stated.
EFFECT: method enables stating the threatened spontaneous miscarriage if any at the early stages of gestation.
SUBSTANCE: invention refers to medicine, and represents a method for the prediction of a risk of congenital infections by measuring specific Ig M and Ig G antibodies in a biological material, differing by the fact that the biological material is presented by the first-screening cervical smear at the 12th week of gestation; the smears are tested for the IgG antibodies to the rubella virus, cytomegalovirus, B19V parvovirus, toxoplasm viruses, type 1 and 2 herpes simplex viruses and an avidity of the specific Ig G to this agents; additionally, the same smear is tested for secretory non-specific Ig A by IFA to cytomegalovirus, Chlamydia, Mycoplasm antigens, and a genetic material of this microorganisms by PCR, and depending on the findings, groups of a high, moderate and low risk of congenital infections are predicted.
EFFECT: invention provides the more accurate prediction of the risk of the most actual congenital infections by the integral assessment of a collection of clinical anamnestic data, and the qualitative parameters of the laboratory findings at the first pregnancy screening.
SUBSTANCE: invention aims at assessing an efficacy of therapeutic agents (TA) for improving individual's cognitive functions. The patient's blood serum is examined for the HLDF protein, titres of idiotypic and anti-idiotypic HLDF antibodies before and after the TA is administered, and the above derived data are used to calculate MMSE before and after the TA is administered by formula; the derived MMSEs are compared, and the TA efficacy is assessed by the comparison result.
EFFECT: invention enables more real-time selection of one or another TA or the length of the course of administration, including the real-time prescription of this course if the patient's condition deteriorates.
3 tbl, 2 ex
SUBSTANCE: invention can be used to assess a risk of cervical cancer accompanying cervical intraepithelial neoplasia and a human papilloma virus (HPV) carrier state in fertile females. That is ensured by sampling cells from the exocervical surface to recover RNA and measuring the gene mRNA expression levels: MKI67, CDKN2A, PGR, BAX. Relating the mRNA expression levels provides calculating a linear discriminant function (LDF): LDF=1.2*lg[CDKN2A]/[BAX]-lg[PGR]/[MKI67]-1, wherein [CDKN2A]/[BAX] is the relation of the CDKN2A and BAX mRNA expression levels, [PGR]/[MKI67] is the relation of the progesterone receptor and MKI67 mRNA expression levels, and if LDF≤0, a low risk of neoplastic transformation is stated; LDF>0 shows a higher risk of neoplastic transformation.
EFFECT: method enables assessing a risk of cervical cancer by the representation of reference genes mRNAs.
2 dwg, 1 ex
SUBSTANCE: invention concerns determining a degree of severity of psychosomatic disorders in patients with discirculatory encephalopathy. That is ensured by a standard therapeutic, neurologic, instrumental examination. That is added with measuring primary anti-S100B protein antibody (AT) titres in blood serum. If the measured titre is up to 150, they should be taken into account in stating degree 3 discirculatory encephalopathy with cognitive disorders reaching moderate or severe dementia accompanied by severe affective and behavioural disorders.
EFFECT: higher specificity, accuracy, sensitivity and reliability of the molecular diagnostic technique.
SUBSTANCE: method comprises inoculation of the test strain on the lawn of the culture, applying a drop of diagnostic phage preparation in centre of the cup, holding at the temperature of 37°C for 20-24 hours and confirmation of its belonging to the microorganisms of the species V. parahaemolyticus in the presence of lysis. At that the diagnostic phage preparation is prepared by mixing phages FC-44 and FC-46, prepared based on the strain Vibrio parahaemolyticus KM-97, in the ratio of 1:1 in the titre n·108 PFU/ml.
EFFECT: present invention enables to accelerate the identification of strains and can be used in the laboratory diagnostics of acute intestinal infections caused by this microorganism.
2 cl, 1 tbl, 3 ex
SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for the prediction of a non-developing pregnancy (NP). Substance of the method: uterine or menstrual aspirate supernatant is examined for carbonyl groups of protein and malondialdehyde at the same time. If the values of the carbonyl groups are 9.43 to 16.91 nmole/ml, and the values of malodialdehyde are 0.71 mcmole/l to 7.28 mcmole/l of malonaldehyde, they are stated to have no negative effect on the endometrium and the gestational sac. If the values of the carbonyl groups fall within the range of 22.32 nmole/mg and more, and if the values of malondialdehyde exceed 7.28 mcmole/l, their negative effect on the gestational sac and a high risk of a non-developing pregnancy are stated. The invention aims at optimising the method for the prediction of a non-developing pregnancy at the pre-clinical stage, at the preventing the negative effect of oxidative stress products on the endometrium at the stage of pre-conceptional preparation.
EFFECT: method is characterised by low invasiveness, technical simplicity, accessibility in women's health clinics and hospitals.
SUBSTANCE: method for acquiring samples for the spectral biochemical blood analysis involving preparing and drying blood serum and extracting for the chromatographic examination differs by the fact that a process of a dry matter of blood serum obtaining is performed with stirring constantly at a temperature of 50-60°C for 21-27 hours to produce the dry matter in the form of a plug compacted in the centre and coated with a superficial film; the plug is perforated with a sterile and chemically intact object; 85% methanol is added to a test tube containing the dry matter. The prepared mixture is placed into the stirring device again at a temperature of 48-52°C for 21-27 hours and compacted in a centrifuge at an acceleration of 11500-12500 g. The prepared sample is added to an auto-sampler test tube of a liquid chromatograph in an amount of 3/4 - 2/3 volumes of the test tube.
EFFECT: using the present invention enables producing chromatograms with a low-error reproducibility within one sample that is adequate to provide the analysis result reliability with the use of t liquid chromatography.